spec sheet11 rows
Rolipram (ZK 62711) is the prototypical PDE4 inhibitor and the reference compound for the entire class. Developed by Schering as an antidepressant in the 1980s, it was abandoned over severe emesis but went on to become the single most-studied molecule in the cAMP/CREB-enhances-memory literature. It reliably converts early- to late-long-term potentiation and rescues memory across Alzheimer, aging and Rubinstein-Taybi models, making it the yardstick every newer PDE4 memory drug is measured against.
- The defining reference compound for PDE4 memory pharmacology
- Robustly enhances memory across many rodent models
- Converts early- to late-LTP and strengthens synaptic tagging in slices
- Drives the cAMP/PKA/CREB/BDNF memory-consolidation pathway
- Worst-in-class emesis: the most emetogenic PDE4 inhibitor tested
- Lowest therapeutic index of the class
- Nausea, vomiting, diarrhea and headache
- No human cognition efficacy; research use only
- Rolipram is the reference PDE4 inhibitor that essentially defined the cAMP/CREB memory hypothesis.
- It began as a 1980s antidepressant candidate but was abandoned because of severe vomiting.
- The very binding-site conformer (HARBS) that drives its memory effect also drives its emesis, which is why the two are so hard to pull apart.
Mechanism
A selective but non-subtype-selective PDE4 inhibitor that binds the high-affinity rolipram binding site (HARBS) conformer, raising , activating PKA and driving to boost , c-Fos and Zif268 while lowering the late- threshold. Critically, the HARBS conformer is linked to both its cognitive potency and its emesis, which is why the two are so hard to separate.
receptor fingerprint
PDE4 (A/B/C/D)Inhibits (non-selective)
HARBS conformer (high-affinity rolipram binding site)Binds
Activates (downstream)
Increases (downstream)
Evidencehow good the literature is
Rodent evidence is strong and extensive: memory enhancement in young and aged mice and rescue in amyloid-beta, APP/PS1, chronic-stress and CBP+/- models. In vitro slice work is equally strong, showing early-to-late-LTP conversion and synaptic tagging. There is no human cognition RCT; historical human use was as an antidepressant only, where emesis capped the dose below the cognitive-efficacy range.
Dosingtypical ranges, not medical advice
interested in protocols and clinical dosages? make an account to see them! ^_^
Safetyrisks and cautions, not medical advice
Truthfully, rolipram has the worst-in-class therapeutic window: it is the most emetogenic PDE4 inhibitor in rat pica benchmarks and has the lowest therapeutic index. Nausea, vomiting, diarrhea and headache dominate. It is the textbook reason PDE4 cognition programs chase rolipram-sparing successors. This is a serious research compound, not a benign nootropic.
History
Synthesized by Schering as ZK 62711 and trialed as an antidepressant in the 1980s, rolipram was shelved for its severe emetic side effects. It found a second life in neuroscience laboratories, where it became the definitive tool for probing how cAMP and CREB signaling strengthen synapses and consolidate memory.
Reputation
In research circles rolipram is iconic: the compound that defined the cAMP/CREB memory hypothesis and against which every later PDE4 memory drug is benchmarked. Among would-be users its reputation is a cautionary one, synonymous with intolerable nausea and a therapeutic window too narrow to use.
Subjective profileweighing the evidence above
Foundational and robustly pro-cognitive in animals, rolipram is the reference point for PDE4 memory pharmacology. Honestly, its brutal emetic profile meant it was never a viable human cognition drug, and it remains a research tool only.
Resources
This entry is here for reference.
Research
- 1998first citedRolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long…
- 2020most recentRolipram treatment during consolidation ameliorates long-term object location memory in aged ma…
- 1.Rolipram, a type IV-specific phosphodiesterase inhibitor, facilitates the establishment of long-lasting long-term potentiation and improves memory.
- 2.Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment.
- 3.Rolipram treatment during consolidation ameliorates long-term object location memory in aged male mice.
- 4.The identification of a novel phosphodiesterase 4 inhibitor, 1-ethyl-5-{5-[(4-methyl-1-piperazinyl)methyl]-1,3,4-oxadiazol-2-yl}-N-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridin-4-amine (EPPA-1), with improved therapeutic index using pica feeding in rats as a measure of emetogenicity.
4 listed here; entry last updated August 2026
Reviews
My notesprivate to this device
FAQ
Is rolipram a usable nootropic?
No. Despite powerful animal data, its severe emesis and narrow therapeutic window make it unusable as a human cognitive enhancer; it is a research tool.
Why is it so important scientifically?
It is the prototypical PDE4 inhibitor that established the cAMP/CREB memory hypothesis and serves as the benchmark for every newer PDE4 memory drug.
Was it ever a medicine?
It was trialed as an antidepressant in the 1980s but abandoned because emesis limited the dose below the effective range.
Adverse effects
- Worst-in-class emesis: the most emetogenic PDE4 inhibitor tested
- Lowest therapeutic index of the class
- Nausea, vomiting, diarrhea and headache
- No human cognition efficacy; research use only